TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Safety of pandemic inactivated influenza vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change in educator instruction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of reoperations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Forearm Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Whole blood gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of motor performance score on the Fugl-Meyer sub-score wrist/hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Alloanti-D Immunization
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of missed TB cases
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Velocity of 10m walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Ocular and Non-ocular TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Dietary quality index for children KidMed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paired Associates Learning (PAL) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Modified Observer Assessment of Alertness/Sedation (MOAA/S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alertness/Drowsiness Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Impressions Global Rating of Improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Response at End of Treatment (EOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Serum Bactericidal Assay Antibody Titers ≥ the Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With rSBA-MenC Antibody Titers ≥ the Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Short-term difference in ventilation defect percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Short-term difference in perfusion defect percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Short-term difference in lung ventilation/perfusion mismatch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quantification of SARS-CoV-2 specific IgG production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Perceived Usefulness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-assessment of dyspareunia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: vaginal cell maturation (Maturation Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: vaginal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Technical success of complete or partial clearance (≥80% stone clearance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean number of lithotripsy and ERCP procedures needed for clearance of stones
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Procedural related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: safety (Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: quality of life (the patient report outcome)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Progression-free Survival, PFS
Endpoint domain: Mortality/survival
Primary endpoint: Change in root dentinal wall width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in apical foramen width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in periodontal healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic and/or para-aortic lymph node involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Scores on the Beck Depression Inventory-II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blastocyst development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Detection of recurrent prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 12-month disease non-progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects maintaining hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With at Least 1 Adverse Event (AE) of Grade 3 or 4
Endpoint domain: Adverse events/effects
Primary endpoint: B12 bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Clinical Scale for Contraversive Pushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum TAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: appetite hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Aerobic capacity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma neurotrophin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rectal Tissue Concentrations of Ralegravir and Dolutegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RNA Concentrations From Gastrointestinal Tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Total CD8+ T-cells With CCR5 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BPDAI (bullous pemphigoid disease area index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: change in gamma oscillations power in the cerebellum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: occurrence of episodes of febrile neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first request of postoperative rescue analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cyst size on Ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in IRLS total score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: change from baseline in MOS sleep disturbance score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Steady-state Average Plasma Concentration (Cavg,ss) of Risperidone and Total Active Moiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in safety behaviors measured by the Safety Behavior Checklist
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Change in State of Change in Enacting Safety Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Change in DASH Symptoms Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston Diagnostic Aphasia Examination Battery (BDAE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stroke Quality of life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Seropositive Subjects for Anti-HPV-16 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seropositive Subjects for Anti-HPV-18 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HPV-16 Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HPV-18 Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Results of the QFT-G test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Results of the TST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the curve of HA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completion of study accrual within study time frame
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physician responses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to issuance of recommendations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of events of Nocturia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cervical Joint Position Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Facial Rosacea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Executive function test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in ICSI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate and extent of absorption of HC-ER 50 mg capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of moderate to severe allergic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Oxygen Level Dependent functional MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomical MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation failure
Endpoint domain: Adverse events/effects
Primary endpoint: Return to pre-injury level of function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recurrence rate of target aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Size of the infarct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 4 or more complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Multidimensional Fatigue Inventory (MFI) score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: in-scaffold minimal lumen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBD medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative Confirmed Major Cytogenetic Response (MCyR) in 2nd and 3rd Line Chronic Phase Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative Confirmed Major Cytogenetic Response (MCyR) in 4th or Later Line Chronic Phase Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative Confirmed Overall Hematological Response (OHR) in Accelerated Phase Chronic Myelogenous Leukemia Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in Serum LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of belinostat
Endpoint domain: Adverse events/effects
Primary endpoint: Change in neuropsychological tests of memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in neuropsychological tests of language
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in neuropsychological tests of visuospatial abilities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in neuropsychological tests of executive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum Plasma Concentration (Css,Max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Paired Associative Stimulation (PAS) induced plasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urea Kt/V
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PK AUC determination of Lu AA21004 (Vortioxetine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK Cmax determination of Lu AA21004 (Vortioxetine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in monocyte oxidative burst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in ex vivo monocyte oxidative burst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: glutamine synthetase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Demonstrated Correct Use of the ELLIPTA DPI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rated the ELLIPTA DPI as Easy to Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of subjects with confirmed rosacea diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ventilation/Perfusion Mismatch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sRAW (k.Pa.s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in outflow facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonization of potential pathogenic microorganisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Liver Fat Fraction reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: T4 / T1 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: average pain during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesions count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Serum Creatinine Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to worsening of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disfigurement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social Interaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Area under the curve (AUC) of absolute neutrophil count (ANC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in 6 Minute Walk Test With VO2 Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital duration after operation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to self-reported repetition of self harm
Endpoint domain: Adverse events/effects
Primary endpoint: gene expression patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insertion rates of implantable birth control
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: high sensitivity C Reactive Protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delta neutrophyl index for thyroid malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immature granulocyte count for thyroid malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neutrophyl to lymphocyte ratio for thyroid malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of conception
Endpoint domain: Mortality/survival
Primary endpoint: AUC(0-12h) of ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of Ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulmonary function (maximal inspiratory pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: electroencephalography (EEG) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eating patterns
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Annual incidence of new-onset type 3c diabetes mellitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in pancreatic fibrosis index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing in Situ Anti-tumor Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bioavailability of tamsulosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression-free survival (PFS) rate at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Pupillary response to blue light
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of social inequalities
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Response at week 6 of investigational window therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unprovoked pain change, post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unprovoked pain change, end of clinical treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unprovoked pain change, one year post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provoked pain change, post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provoked pain change, end of clinical treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provoked pain change, one year post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 400-meter walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous filling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Assessment of Chronic Illness Care (PACIC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Treatment-Emergent Graded Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of Remdesivir and Its Metabolites GS-704277 and GS-441524 at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau of Remdesivir and Its Metabolites GS-704277 and GS-441524 at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GERD-HRQL scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With CSF Prescribed as Primary Prophylaxis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Febrile Neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Febrile Neutropenia Among Intermediate Risk Participants
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of CA125 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Substance use rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clozapine blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of parenchymal hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the curve of postprandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of Myocardial Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Performance and accuracy in glucose monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Performance and accuracy in pO2 monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes